Bio-Techne

Health Care Life Sciences Tools & Services Minneapolis, Minnesota Last filing Aug 22, 2025 · FY2025

                    Revenue
                    FY2025
                
$1.2B
                    3y CAGR +3.3%
                    
                    P39
                    
                    n/a
                    
                    Net income
                    FY2025
                
$73.4M
                    Net margin +6.0%
                    
                    P28
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$2.6B
                    ROA +2.9%
                    
                    P17
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$287.6M
                    FCF margin +21.0%
                    
                    P73
                    
                    n/a

17 yrs · FY2009–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

29 accounts · 1 year

Total assets $2.6B

Total liabilities $175.8M

Shareholders equity $1.9B

Account	2025	Trend
Assets
Cash and Cash Equivalents	13.3%
Accounts Receivable	17.0%
Inventory	15.5%
Prepaid Expenses	3.1%
Other Current Assets	3.1%
Total Current Assets	49.9%
Property,Plant and Equipment	20.1%
Operating Lease Assets	6.0%
Goodwill	80.4%
Intangible Assets	30.0%
Long Term Investments	19.3%
Other Noncurrent Assets	22.4%
Total Assets	209.7%
Liabilities
Accounts Payable	2.1%
Accrued Liabilities	2.1%
Deferred Revenue	2.7%
Operating Lease Liabilities	1.2%
Other Current Liabilities	0.1%
Total Current Liabilities	14.4%
Operating Lease Liabilities Noncurrent	6.9%
Deferred Tax Liabilities	0.5%
Other Noncurrent Liabilities	2.2%
Total Liabilities	14.4%
Equity
Common Stock	0.1%
Additional Paid In Capital	74.7%
Retained Earnings	87.4%
Accumulated Other Comprehensive Income	-4.9%
Total Stockholders Equity	157.3%
Total Liabilitiesand Equity	209.7%

Income Statement

Revenue, expense, and profitability

20 accounts · 1 year

Revenue $1.2B

Operating income $102.3M

Net income $73.4M

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	35.2%
Expenses Research and Development	8.2%
Expenses Selling,General and Administrative	48.3%
Expenses Depreciation and Amortization	9.0%
Expenses Share Based Compensation	3.3%
Expenses Operating Expenses	56.4%
Other Income Expense Gross Profit	64.8%
Other Income Expense Operating Income	8.4%
Other Income Expense Interest Income	0.3%
Other Income Expense Interest Expense	0.7%
Other Income Expense Other Income/expense	0.1%
Other Income Expense Income Before Tax	8.1%
Income Tax Income Tax Expense	2.1%
net Income net Income	6.0%
net Income Comprehensive Income	7.5%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	12.9%
Earnings Per Share Weighted Average Shares Diluted	13.1%

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 1 year

Operating cash flow $287.6M

Investing cash flow $-35.2M

Financing cash flow $-253.9M

Account	2025	Trend
CashFlow
Operating Activities net Income	6.0%
Operating Activities Depreciation and Amortization	9.0%
Operating Activities Stock Based Compensation	3.3%
Operating Activities Deferred Income Taxes	-4.2%
Operating Activities Changes In Operating Assets and Liabilities	1.5%
Operating Activities Other Non Cash Items	0.1%
Operating Activities net Cash From Operating Activities	23.6%
Investing Activities Capital Expenditures	2.5%
Investing Activities Other Investing Activities	0.0%
Investing Activities net Cash From Investing Activities	-2.9%
Financing Activities Repayment of Debt	6.3%
Financing Activities Repurchase of Common Stock	22.6%
Financing Activities Dividends Paid	4.1%
Financing Activities Proceeds From Stock Issuance	4.2%
Financing Activities Tax Withholding On Stock Based Compensation	0.5%
Financing Activities net Cash From Financing Activities	-20.8%
Cash Reconciliation Effect of Exchange Rate On Cash	1.0%
Cash Reconciliation net Change In Cash	0.9%
Cash Reconciliation Cash At Beginning of Period	13.3%
Cash Reconciliation Cash At End of Period	13.3%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+64.8%
Operating margin	+8.4%
Net margin	+6.0%
FCF margin	+21.0%
Growth
Revenue CAGR (3y)	+3.3%
Returns
ROE	+3.8%
ROA	+2.9%
ROIC	—
Liquidity
Current ratio	3.46x
Quick ratio	2.10x
Leverage
D/E	0.09x
Interest coverage	12.02x
Efficiency
Asset turnover	0.48x
Cash conversion cycle	+201d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Bio-Techne

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history